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An analytical method based on ultra-performance liquid chromatography with positive ion electrospray
ionization (ESI) coupled with tandem mass spectrometry detection (UPLC–MS/MS) was developed and
validated for the determination of therapeutic peptide desmopressin in human plasma. A desmopressin
stable labeled isotope (desmopressin d8) was used as an internal standard. Analyte and the internal
standard were extracted from 200 mL of human plasma via solid-phase extraction technique using Oasis
WCX cartridges. The chromatographic separation was achieved on an Aquity UPLC HSS T3 column by
using a gradient mixture of methanol and 1 mM ammonium formate buffer as the mobile phase. The
calibration curve obtained was linear (r2Z0.99) over the concentration range of 1.01–200 pg/mL.
Method validation was performed as per FDA guidelines and the results met the acceptance criteria. The
results of the intra- and inter-day precision and accuracy studies were well within the acceptable limits.
The proposed method was successfully applied to pharmacokinetic studies in humans.
& 2015 Xi'an Jiaotong University. Production and hosting. Published by Elsevier B.V. All rights reserved.1. Introduction
Desmopressin is a synthetic analog of vasopressin, a natural pi-
tuitary hormone with antidiuretic properties. The deamination of va-
sopressin in the N-terminal 1 position and replacement of 8-L-arginine
with 8-D-arginine results in the formation of desmopressin. It has a
longer duration of antidiuretic activity than that of the natural hor-
mone and is essentially devoid of other associated pharmacological
effects such as vasoconstriction and contraction of smooth muscles in
the uterus or in the intestine [1–3]. This prolonged and speciﬁc anti-
diuretic effect makes desmopressin useful for managing a number of
enuretic disorders, including nocturia, primary nocturnal enuresis and
central diabetes insipidus [4,5]. The oral administration of desmo-
pressin is shown to be safe and effective for treating central diabetes
insipidus and primary nocturnal enuresis [6]. The low doses of des-
mopressin (0.200–1.20 mg per day) may result in very low plasma
concentrations. Therefore, a highly sensitive and selective method for
the determination of therapeutic levels during clinical studies is
required.
According to the literature, few liquid chromatography/mass
spectrometric methods (LC–MS) have been reported for theon and hosting. Published by Elsev
University.
K. Gudlawar).
et al., Highly sensitive assa
. Anal. (2015), http://dx.doiquantitative determination of desmopressin in skin samples [7],
blood plasma samples [8] and in urine samples [9]. Also, an LC–MS
method [10] has been reported for the qualitative detection of
desmopressin in human plasma samples for doping control pur-
pose. Most of the analytical methods [7,9,10] reported so far were
too insensitive and/or not suitable for quantitative determination
of desmopressin in human plasma samples for pharmacokinetic/
bioequivalence studies. However, a promising method was re-
ported by Nguyen et al. [8] with an LOQ of 2 pg/mL and employs
multi-step solid phase extraction involving many stringent
method development protocols with a chromatographic run time
of 418 min, which may not be favorable for routine drug analysis.
This method utilizes a single-quadrupole mass spectrometry with
selected-ion monitoring (SRM) mode to detect the precursor ion.
But in the present method a triple-quadrupole mass spectrometry
(LC–MS/MS) with multiple reaction monitoring (MRM) mode was
used to detect both the precursor ion and fragment ion. It shows
that the proposed method is highly speciﬁc. Moreover, the method
reported by Nguyen et al. [8] does not describe the development
process, volume of the sample used, various validation experi-
ments, stability studies and suitability for application to pharma-
cokinetic/bioequivalence studies. The salient features of chroma-
tographic methods developed for desmopressin in human plasma
are summarized in Table 1.
This paper presents, for the ﬁrst time, the complete develop-
ment and validation of a simple, highly sensitive and selectiveier B.V. All rights reserved.
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Please cite this article as: S.K. Gudlawar, et al., Highly sensitive assa
human plasma by UPLC–MS/MS, J. Pharm. Anal. (2015), http://dx.doiUPLC-MS/MS method in MRM mode for the quantiﬁcation of
desmopressin in human plasma using desmopressin d8 as an in-
ternal standard (IS). This sensitive method (1.01 pg/mL) requires
only 200 mL human plasma for solid-phase extraction (SPE) tech-
nique, minimum usage of organic solvents and demonstrates ex-
cellent performance in terms of ruggedness with a sample cut off
time of 7.0 min. The application of this assay method to a clinical
pharmacokinetic study in healthy South Indian male subjects fol-
lowing oral administration of desmopressin is described under
fasting condition. The authenticity in the measurement of study
data is demonstrated through incurred samples reanalysis.2. Experimental
2.1. Chemicals and reagents
Reference sample desmopressin (Z97%) and the internal standard
(IS) desmopressin d8 (Z97%) were purchased from Sigma-Aldrich
Limited (Bengaluru, India). LCMS grade methanol was purchased from
J.T. Baker (Phillipsburg, USA). Analytical grade ammonium formate,
formic acid and acetic acid were purchased from Merck Ltd (Mumbai,
India). Water used for the LC–MS/MS analysis was prepared by using
Milli Q water puriﬁcation system procured from Millipore (Bangalore,
India). The control human plasma sample was procured from Deccan′s
Pathological Lab′s (Hyderabad, India).
2.2. UPLC–MS/MS instrument and conditions
An UPLC system (Waters Corporation, Milford, USA) consisting
of an Aquity HSS T3 column (100 mm2.1 mm, 1.8 mm; Waters
corporation, Milford, USA) equipped with a binary pump and a 96-
vial autosampler (Waters, Milford, USA) was used for the study.
Aliquots of 20 mL of the processed samples were injected into the
column, which was kept at 40 °C. A mobile phase consisting of a
mixture of 1 mM ammonium formate buffer (solvent A) and me-
thanol (solvent B) in a gradient proportion was used to separate
the analyte from the endogenous components. The gradient pro-
gram was run from 25% B to 75% B in 3 min and ramped up to 90%
B within 0.2 min and held for 1 min and ramped down to initial
conditions within 0.25 min and stayed there for 2.0 min. Flow
gradient was also performed starting with 0.4 mL/min up to
1.5 min, then 0.2 mL/min within 0.25 min and stayed for 1.75 min
and ﬂow came back to initial ﬂow.
Quantiﬁcation was achieved with MS–MS detection in positive
ion mode (ESþ) for the analyte and the internal standard using a
Waters XEVO TQ-S mass spectrometer (Manchester, United King-
dom). The source temperature, desolvation temperature and des-
olvation gas ﬂow were set at 150 °C, 500 °C and 1000 L/h, re-
spectively. The capillary voltage, cone voltage and collision energy
were 1.6 kV, 30 V, 14 V for desmopressin and 1.6 kV, 25 V, 12 V
for the IS. The dwell time for each transition was 75 ms and argon
gas was operated at 3.5103 bar. Detection of the ions was
carried out in the MRM mode, by monitoring the transition pairs
of m/z 535.5 precursor ion to the m/z 328.3 production for des-
mopressin and m/z 539.7 precursor ion to the m/z 328.4 product
ion for the IS. The analysis data obtained were processed by
Masslynx SCN 843 (Version 4.1).
2.3. Preparation of plasma standards and quality controls
Standard stock solution of desmopressin and the IS (0.1 mg/mL)
was prepared in water. Working solutions for calibration and
controls were prepared by appropriate dilution in water. The IS
working solution (1 ng/mL) was prepared by diluting its stock
solution with water.y for the determination of therapeutic peptide desmopressin in
.org/10.1016/j.jpha.2013.11.002i
S.K. Gudlawar et al. / Journal of Pharmaceutical Analysis ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 3The above working solutions (50 mL) were added to drug-free
plasma (950 mL) as a bulk, to obtain desmopressin concentration
levels of 1.01, 2.35, 5.37, 11.2, 40.1, 80.1, 120, 160, and 200 pg/mL as
a single batch at each concentration. Similarly, quality control (QC)
samples were also prepared as a bulk based on an independent
weighing of standard drug, at concentrations of 1.01 (LLOQ), 3.05
(low), 78.14 (middle) and 156.23 pg/mL (high) as a single batch at
each concentration. The calibration and control bulk samples were
divided into aliquots in microcentrifuge tubes (Tarson, 2 mL) and
stored in the freezer at 2075 °C until analyses.
2.4. Sample processing
All frozen subject samples, calibration standards and quality
control samples were thawed and allowed to equilibrate at room
temperature prior to analysis. The samples were vortexed to mix
for 10 s prior to spiking. A 200 mL aliquot of human plasma sample
was mixed with 25 μL of the internal standard working solution
(1 ng/mL of desmopressin d8). To this, 200 μL of 2% acetic acid
solution was added after vortex mixing for 10 s. The sample mix-
ture was loaded onto an Oasis WCX 1 cm3 (30 mg/ mL) that was
pre-conditioned with 1.0 mL of methanol followed by 1.0 mL of
water. The extraction cartridge was washed with 1.0 mL of 5%
ammonia solution followed by 1.0 mL of methanol. Analyte and IS
were eluted with 1.0 mL of 2% formic acid in methanol and eva-
porated at 45 °C under a gentle stream of nitrogen. The dried ex-
tract was reconstituted with 200 mL mixture of 1 mM ammonium
formate and methanol (70:30, v/v). Aliquot of 20 μL of the extract
was injected into the chromatographic system.
2.5. Bioanalytical method validation
The validation of the above method was carried out as per US
FDA guidelines [11]. The parameters determined were selectivity,
speciﬁcity, sensitivity, matrix effect, linearity, precision, accuracy,
recovery, dilution integrity and stability. Selectivity was assessed
by comparing the chromatograms of eight different batches of
blank plasma obtained from six different sources including one
lipemic and hemolyzed plasma. Sensitivity was determined by
analyzing six replicates of plasma samples spiked with the lowest
level of the calibration curve concentrations. Carry-over experi-
ment was performed to verify any carryover of analyte and IS,
which may reﬂect in subsequent runs. The design of the study
comprised the following sequence of injections i.e., blank plasma
sample-six samples of LLOQ-blank plasma sample- upper
limit of quantitation (ULOQ) sample-blank plasma samples to
check for any interference due to carry-over.
Matrix effect was checked with six different lots of K2 EDTA
plasma. Three replicate samples each of LQC and HQC were pre-
pared from different lots of plasma (36 QC samples in total). For
checking the linearity standard calibration curves containing at
least 9 points (non–zero standards) were plotted. In addition,
blank plasma samples were also analyzed to conﬁrm the absence
of direct interferences. To determine intra-day accuracy and pre-
cision, a calibration curve and six replicates of LLOQ QC, LQC, MQC
and HQC were analyzed on the same day. Inter-day accuracy and
precision were assessed by analyzing three batches of samples on
two consecutive days. Recoveries of analyte and IS were de-
termined by comparing the peak area of extracted analyte stan-
dard with the peak area of non-extracted standard. Recovery of
desmopressin was determined at a concentration of 3.05 (low),
78.1 (middle) and 156.23 (high) pg/mL, whereas for IS it was de-
termined at concentration of 1.00 ng/mL. Dilution integrity was
performed to extend the upper concentration limit with accep-
table precision and accuracy. Six replicates each at a concentration
of about 1.80 times of the uppermost calibration standard werePlease cite this article as: S.K. Gudlawar, et al., Highly sensitive assa
human plasma by UPLC–MS/MS, J. Pharm. Anal. (2015), http://dx.doidiluted two- and four-fold with blank plasma. The diluted samples
were processed and analyzed.
Stability tests were conducted to evaluate the analyte stability
in stock solutions and in plasma samples under different condi-
tions. The stock solution stability at room temperature and re-
frigerated conditions (2–8 °C) was performed by comparing the
area response of the analyte (stability samples) with the response
of the sample prepared from fresh stock solution. Bench top sta-
bility (6 h), processed samples stability (autosampler stability for
48 h, wet extract stability for 45 h and reinjection stability for
24 h), freeze–thaw stability (three cycles), long-term stability (30
days) were performed at LQC and HQC levels using six replicates at
each level. Samples were considered to be stable if assay values
were within the acceptable limits of accuracy (715% SD) and
precision (r15% RSD).
2.6. Pharmacokinetic study design
A pharmacokinetic study was performed in healthy male sub-
jects (n¼6) and an ethical vote was obtained from the local ethics
commission. The subjects were fasted 9 h before administration of
the drug formulation. Blood samples were collected following oral
administration of 0.4 mg (20.2 mg) desmopressin at pre-dose
and 0.167, 0.333, 0.5, 0.667, 0.833, 1, 1.25, 1.5, 1.75, 2, 3, 4, 5, 6, 8, 10,
12, and 16 h, in K2 EDTA vacutainer collection tubes (BD, Franklin,
NJ, USA). The tubes were centrifuged at 3200 rpm for 10 min and
the plasma was collected. The collected plasma samples were
stored at 2075 °C till their use. Plasma samples were spiked
with the IS and processed as per the extraction procedure de-
scribed earlier. Plasma concentration–time proﬁle of desmopressin
was analyzed by non-compartmental method using WinNonlin
Version 5.1. An incurred sample reanalysis was also conducted by
selecting the 12 subject samples (two samples from each subject)
near Cmax and the elimination phase. The percent change in the
value should not be more than 720% [12,13].3. Results and discussion
3.1. Mass spectrometry
Mass parameters were tuned in both positive and negative ioni-
zation modes using electrospray ionization source. The intensity re-
sponse obtained in positive mode was much higher than those in
negative ion mode since the analyte and IS have the ability to accept
protons. Protonated form of analyte and IS [MþH]þ ionwas the parent
ion in the Q1 spectrum and was used as the precursor ion to obtain Q3
product ion spectra. The most sensitive mass transition was observed
fromm/z 535.5 to 328.3 for desmopressin and fromm/z 539.7 to 328.4
for the IS. LC–MRM is a very powerful technique for pharmacokinetic
studies since it provides sensitivity and selectivity requirements for
analytical methods [14]. Thus, the MRM technique was chosen for the
assay development.
3.2. Method development
The development of sensitive and selective bioanalytical
method requires the judicious selection of chromatography col-
umn, mobile phase and organic solvent. These parameters should
be carefully monitored to produce the required resolution from
endogenous components which in turn affect sensitivity and re-
producibility of the analytical method by ion suppression. Once
chromatographic column, mobile phase pH and organic solvent
are set then gradient slope, ﬂow rate, column temperature and
buffer type and concentration can be manipulated for optimal
response.y for the determination of therapeutic peptide desmopressin in
.org/10.1016/j.jpha.2013.11.002i
Fig. 1. Effect of organic solvent on multiply charging. (A) methanol and (B) acetonitrile.
S.K. Gudlawar et al. / Journal of Pharmaceutical Analysis ∎ (∎∎∎∎) ∎∎∎–∎∎∎4Organic solvents such as acetonitrile and methanol were tried
in different volume ratio with buffers like ammonium acetate,
ammonium formate as well as acid additives like acetic acid and
formic acid in varying strength. It was observed that methanol and
1 mM ammonium formate buffer as the mobile phase at gradient
composition was most appropriate to give best sensitivity, efﬁ-
ciency and peak shape. Acetonitrile showed more of singly
charged spectrum compared to methanol, where doubly charged
species was dominating, so methanol has been chosen as an or-
ganic solvent as shown in Fig. 1. Initially, separation was tried on
different columns like Waters Aquity BEH C18, HSS T3, CSH C18,
etc. The use of an Aquity HSS T3 column (100 mm2.1 mm,
1.8 mm) gave good peak shapes and response even at the lowest
concentration level for the analyte and IS. The mobile phase was
operated at a gradient ﬂow mode. The retention time of analyte
and the IS was low enough (3.3 and 3.3 min) allowing a run time
of 7.0 min.
To develop a highly sensitive (pg level) analytical method in
human plasma samples, one should have a proper extraction
method which can produce good recovery with minimal or no
matrix effect. Initially both the extraction methodologies protein
precipitation (PP) and liquid–liquid extraction (LLE) were tried
with acetonitrile, acetone and methanol for PP and different or-
ganic solvents like ethyl acetate, hexane, dichloromethane, diethyl
ether and methyl tert-butyl ether (MTBE) for LLE. The recovery
results obtained were inconsistent with ion suppression in both
the occasions. Moreover, the response was not enough to quantify
the analyte at LLOQ level.
But for the purpose to develop a highly sensitive and speciﬁc
method, SPE was tested. Moreover, SPE technique provides clear
extracts than the PP and LLE and the inﬂuence on sensitivity is
considerably small. Hence SPE was tried using Oasis HLB, MCX,
MAX, and WCX cartridges. Among the different cartridges tested,
WCX cartridges gave clear extracts with minimum matrix effectPlease cite this article as: S.K. Gudlawar, et al., Highly sensitive assa
human plasma by UPLC–MS/MS, J. Pharm. Anal. (2015), http://dx.doiand quantitative extraction was possible for the analyte and IS.
Addition of acetic acid solution to the plasma samples in different
volume ratios helped in obtaining consistent and reproducible
response. When eluent was injected directly into the UPLC system,
the peak shape of analyte was unacceptable at lower concentra-
tion levels and also the response was insufﬁcient to quantify the
analyte. Hence eluent was evaporated and the residue was re-
constituted using a mixture of 1 mM ammonium formate and
methanol (70:30, v/v). The overall mean recoveries of analyte and
the IS were good and reproducible. Moreover, the validation re-
sults and subject sample analysis study support this extraction
methodology and hence it was accepted in the present study.
Stable labeled isotopes of the analyte as an internal standard
(IS) is recommended for bioanalytical assays to increase assay
precision and limit variable recovery between analyte and the IS
[15,16]. Also for LC–MS/MS analysis, using stable isotope-labeled
drugs as internal standards proves to be helpful when a signiﬁcant
matrix effect is possible. At the initial stages of this work, several
compounds were investigated to ﬁnd a suitable IS and ﬁnally
desmopressin stable labeled isotope desmopressin d8 was found to
be best for the present purpose.
3.3. Method validation
3.3.1. Chromatography, selectivity and carryover effect
The selectivity of the method was examined by analyzing blank
human plasma extract (Fig. 2A) and an extract spiked only with
the IS (Fig. 2B). As shown in Fig. 2A, no signiﬁcant direct inter-
ference in the blank plasma traces was observed from endogenous
substances in drug-free human plasma at the retention time of the
analyte and IS. Similarly, Fig. 2B shows the absence of direct in-
terference from the IS to the MRM channel of the analyte. Fig. 2C
depicts a representative ion-chromatogram for the LLOQ sample
(1.01 pg/mL). A representative chromatogram resulting from they for the determination of therapeutic peptide desmopressin in
.org/10.1016/j.jpha.2013.11.002i
Fig. 2. Typical MRM chromatograms of desmopressin (left panel) and IS (right panel) in human blank plasma (A), human plasma spiked with IS (B), and an LLOQ sample
along with IS (C).
S.K. Gudlawar et al. / Journal of Pharmaceutical Analysis ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 5analysis of subject blank plasma sample and 1.25 h subject plasma
sample after the administration of a 0.4 mg oral single dose of
desmopressin is shown in Fig. 3. No area of analyte was observed
in blank plasma samples run after ULOQ, which suggests no carry-
over of the analyte in subsequent runs.Please cite this article as: S.K. Gudlawar, et al., Highly sensitive assa
human plasma by UPLC–MS/MS, J. Pharm. Anal. (2015), http://dx.doi3.3.2. Sensitivity
The lowest limit of reliable quantiﬁcation for the analyte was
set at the concentration of the LLOQ (1.01 pg/mL). The precision
and accuracy of analyte at LLOQ concentration were found to be
4.10% and 107.8%, respectively.y for the determination of therapeutic peptide desmopressin in
.org/10.1016/j.jpha.2013.11.002i
Fig. 3. MRM chromatograms resulting from the analysis of subject blank plasma sample (A) and 1.25 h subject plasma sample (B), after the administration of a 0.4 mg oral
single dose of desmopressin tablet. The sample concentration was determined to be 36.10 pg/mL.
S.K. Gudlawar et al. / Journal of Pharmaceutical Analysis ∎ (∎∎∎∎) ∎∎∎–∎∎∎63.3.3. Matrix effect
Matrix effect assessment was done with the aim to check the effect
of different lots of plasma on the back calculated value of QC’s nominal
concentration. The precision and accuracy for desmopressin at LQC
concentrationwere found to be 2.05% and 101%, and at HQC level they
were 1.21% and 101%, respectively. Results revealed that no signiﬁcant
matrix effect was observed in all the eight batches of human plasma
for the analyte at low and high quality control concentrations. Also, the
extraction method was rugged enough and gave accurate and con-
sistent results when applied to real subject samples.Please cite this article as: S.K. Gudlawar, et al., Highly sensitive assa
human plasma by UPLC–MS/MS, J. Pharm. Anal. (2015), http://dx.doi3.3.4. Linearity, precision and accuracy
The nine-point calibration curve was found to be linear over the
concentration range of 1.01–200 pg/mL for desmopressin. After com-
paring the two weighting models (1/x and 1/x2), a regression equation
with a weighting factor of 1/x2 of the drug to the IS concentration was
found to produce the best ﬁt for the concentration–detector response
relationship. The mean correlation coefﬁcient of the weighted cali-
bration curves generated during the validation was Z0.99.
The results for intra-day and inter-day precision and accuracy
in plasma quality control samples are summarized in Table 2. They for the determination of therapeutic peptide desmopressin in
.org/10.1016/j.jpha.2013.11.002i
Table 2
Precision and accuracy data for desmopressin.
Quality
control
Run Concentration found
(mean7SD; pg/mL)
Precision (%) Accuracy (%)
Intra-day variationsa
LLOQ 1 1.1070.04 4.54 109.22
2 0.9870.03 3.16 97.21
3 1.0870.06 5.08 107.23
LQC 1 2.9870.21 7.28 97.82
2 3.1870.29 9.27 104.44
3 3.0370.09 3.24 99.50
MQC 1 81.4572.40 2.18 104.23
2 80.5171.63 2.51 103.03
3 80.5771.60 2.82 103.14
HQC 1 159.5373.22 1.71 102.11
2 161.2970.82 0.55 103.24
3 159.8974.83 2.04 102.34
Inter-day variationsb
LLOQ 1.0970.06 5.11 108.22
LQC 3.1270.01 2.90 102.27
MQC 77.0873.12 4.10 98.64
HQC 155.1774.64 2.03 99.32
Spiked concentrations of LLOQ, LQC, MQC, and HQC are 1.01, 3.05, 78.14,
156.23 pg/mL, respectively.
a Six replicates at each concentration.
b Eighteen replicates at each concentration.
Table 3
Stability data for desmopressin in plasma (n¼6).
Stability test QC (spiked con-
centration; pg/mL)
Mean7SD
(ng/mL)
Precision (%) Accuracy/
stability (%)
Processa 3.05 2.9070.21 4.24 95.11
156.23 152.6876.25 5.16 97.73
Processb 3.05 2.8970.22 6.03 94.84
156.23 154.9873.25 3.41 99.20
Bench topc 3.05 2.9270.13 4.22 95.67
156.23 146.5677.26 9.88 93.81
FTd 3.05 2.8370.52 8.26 92.70
156.23 142.3971.56 1.13 91.14
Reinjectione 3.05 3.0570.23 3.60 99.96
156.23 158.0473.10 2.62 101.06
Long-termf 3.05 3.3370.17 5.22 109.12
156.23 144.8974.41 3.18 92.74
a After 48 h in autosampler at 10 °C.
b After 45 h at 2–8 °C.
c After 6 h at room temperature.
d After three freeze and thaw cycles.
e After 24 h of reinjection.
f At 20 °C for 30 days.
Fig. 4. Mean plasma concentration–time proﬁle of desmopressin in human plasma
following oral administration of desmopressin 0.4 mg to healthy volunteers (n¼6).
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15% of the relative standard deviation (RSD) at low, middle and
high quality control levels, whereas within 20% at LLOQ QCs level.
The intra-day and inter-day accuracy deviation values were all
within 100715% of the actual values at low, middle and high
quality control levels, whereas within 100720% at LLOQ QCs level.
The results revealed good precision and accuracy.
3.3.5. Extraction efﬁciency
Six replicates at low, middle and high quality control con-
centrations for desmopressin were prepared for recovery de-
termination. SPE with WCX cartridges proved to be robust and
provided the cleanest samples. The mean overall recovery of
desmopressin was 77.372.38% with the precision range of 3.21–
5.28% and the recovery of IS was 77.772.90% with the precision
range of 1.06–1.63%. The recoveries of analyte and IS were good
and reproducible. Therefore, the assay has been proved to be ro-
bust in high throughput bioanalysis.
3.3.6. Effect of dilution factor
The upper concentration limit of desmopressin can be ex-
tended to 360 pg/mL for by 1/2 and 1/4 dilutions with screened
human blank plasma. The mean back-calculated concentrations for
1/2 and 1/4 dilution samples were within 85–115% of their nom-
inal value. The coefﬁcients of variation (%CV) for 1/2 and 1/4 di-
lution samples were less than 15%.
3.3.7. Stability studies
In the different stability experiments carried out, namely, bench
top stability (6 h), autosampler stability (48 h), repeated freeze–thaw
cycles (three cycles), reinjection stability (24 h), wet extract stability
(45 h at 2–8 °C) and long term stability at 2075 °C for 30 days the
mean% nominal values of the analyte were found to be within 715%
of the predicted concentrations for the analyte at their LQC and HQC
levels (Table 3). Thus, the results were found to be within the accep-
table limits during the entire validation.
Stock solutions of desmopressin and IS were found to be stable
for 15 days at 2–8 °C. The percentage stability (with the precision
range) of desmopressin and IS was 104% (2.11–3.24%) and 99.6%
(0.81–1.56%), respectively.Please cite this article as: S.K. Gudlawar, et al., Highly sensitive assa
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In order to verify the sensitivity and selectivity of this method
in a real-world situation, the present method was used to test for
desmopressin in human plasma samples collected from healthy
male volunteers (n¼6). The mean plasma concentrations versus
time proﬁle of desmopressin is shown in Fig. 4. The maximum
concentration (Cmax) in plasma (35.078.10 pg/mL) for desmo-
pressin was attained at 1.4070.48 h (tmax). The area under the
plasma concentration–time curve from time zero to last measur-
able time point (AUC0–t) and area under the plasma concentra-
tion–time curve from time zero to inﬁnity time point (AUC0–inf) for
desmopressin were 149746 and 157751 pg h/mL, respectively.
The terminal half-life (t1/2) was found to be 3.4870.50 h.
3.5. Incurred sample reanalysis
In order to assess the suitability of the validated LC–MS/MS
method incurred samples were analyzed and data were then
compared using incurred sample reproducibility (ISR) procedure
and criteria [12,13]. The ISR was performed using two plasma
samples from each subject and re-assayed in a separate batch run.
The differences in concentrations between the ISR and the initialy for the determination of therapeutic peptide desmopressin in
.org/10.1016/j.jpha.2013.11.002i
Table 4
Incurred samples re-analysis data of desmopressin.
Sample Initial conc. (pg/mL) Re-assay conc. (pg/mL) Differencea (%)
1 35.20 36.26 –2.96
2 4.01 4.15 –3.33
3 24.49 22.85 6.93
4 3.58 3.19 11.41
5 27.86 26.87 3.60
6 3.18 3.24 –1.81
7 29.30 30.25 –3.22
8 3.18 3.29 –3.37
9 35.03 34.23 2.32
10 3.04 2.69 12.43
11 33.45 32.84 1.85
12 3.81 3.47 9.54
a Expressed as [(initial conc.re-assay conc.)/average]100%.
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indicating good reproducibility of the present method.4. Conclusions
The results presented here demonstrate the successful devel-
opment and validation of a highly sensitive and selective UPLC–
MS/MS method for the determination of desmopressin in human
plasma samples. To the best of the authors’ knowledge, this is the
ﬁrst UPLC–MS/MS report describing the complete method devel-
opment and validation process for the determination of desmo-
pressin in human plasma. This method is highly sensitive and
employs 200 mL plasma volumes for sample processing. The
method showed suitability for clinical studies in humans. From the
results of all the validation parameters, we can conclude that the
developed method can be useful for bioavailability and bioequi-
valence (BA/BE) studies and routine therapeutic drug monitoring
with the desired precision and accuracy.Acknowledgments
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